Generian Pharmaceuticals
About Generian Pharmaceuticals
Generian Pharmaceuticals utilizes a proprietary drug discovery platform to identify orally bioavailable small molecules that modulate protein stability through activation, stabilization, or degradation. This approach targets diseases with high unmet needs, particularly those currently treated with biologics, enhancing patient access and reducing treatment costs.
```xml <problem> Many diseases, particularly those currently treated with biologics, have high unmet needs due to limitations in patient access, high treatment costs, and challenges in achieving optimal drug titration. Biologic drugs often require intravenous administration, limiting convenience and accessibility for patients. </problem> <solution> Generian Pharmaceuticals is developing orally bioavailable small molecule therapeutics that modulate protein stability to address diseases currently dominated by biologics. Their proprietary drug discovery platform identifies small molecules that can activate, stabilize, or degrade target proteins, offering a more convenient and cost-effective alternative to biologics. By focusing on small molecules, Generian aims to improve patient access, reduce treatment costs, and enable more precise drug titration compared to traditional antibody-based therapies. The company's approach allows for screening proteins in their native cellular environment, potentially unlocking previously undruggable targets. </solution> <features> - Proprietary drug discovery platform for identifying small molecules that modulate protein stability - Focus on orally bioavailable small molecules for improved patient convenience - Capability to screen proteins of interest in their native cellular environment - Identification of target binders through highly translational phenotypic screening - Pipeline of first-in-class drug candidates that therapeutically modulate target protein structure and/or dynamics - Programs targeting both clinically validated targets and novel targets through a research collaboration agreement </features> <target_audience> The primary target audience includes patients with diseases currently treated with biologics, as well as pharmaceutical companies seeking novel small molecule therapeutics for difficult-to-drug targets. </target_audience> ```
What does Generian Pharmaceuticals do?
Generian Pharmaceuticals utilizes a proprietary drug discovery platform to identify orally bioavailable small molecules that modulate protein stability through activation, stabilization, or degradation. This approach targets diseases with high unmet needs, particularly those currently treated with biologics, enhancing patient access and reducing treatment costs.
Where is Generian Pharmaceuticals located?
Generian Pharmaceuticals is based in Pittsburgh, United States.
When was Generian Pharmaceuticals founded?
Generian Pharmaceuticals was founded in 2019.
How much funding has Generian Pharmaceuticals raised?
Generian Pharmaceuticals has raised 12990000.
- Location
- Pittsburgh, United States
- Founded
- 2019
- Funding
- 12990000
- Employees
- 6 employees